高级检索
当前位置: 首页 > 详情页

High expression of DOCK2 indicates good prognosis in acute myeloid leukemia

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China [2]Department of Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA [3]Department of Operations and Information Management, China-Japan Friendship Hospital, Beijing, 100029, China [4]Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands [5]Department of Respiratory, Huaihe Hospital of Henan University, Kaifeng, 475000, China [6]Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, 100853, China [7]Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China [8]Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China [9]Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China [10]Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China
出处:
ISSN:

关键词: acute myeloid leukemia DOCK2 allogeneic hematopoietic stem cell transplantation chemotherapy prognosis

摘要:
DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML). We first analyzed data of 85 AML patients who were treated with chemotherapy and had available DOCK1 to DOCK11 expression information and found that DOCK1 and DOCK2 had prognostic significance in AML. In view of the known prognosis of DOCK1 in AML, we then explored the prognostic role of DOCK2. One hundred fifty-six AML patients with DOCK2 expression data were extracted from The Cancer Genome Atlas (TCGA) database and enrolled in this study. Patients were divided based on treatment modality into the chemotherapy group and the allogeneic hematopoietic stem cell transplant (allo-HSCT) group. Each group was divided into two groups by the median expression levels of DOCK2. In the chemotherapy group, high DOCK2 expression was associated with longer event-free survival (EFS, P=0.001) and overall survival (OS, P=0.007). In the allo-HSCT group, EFS and OS were not significantly different between high and low DOCK2 expression groups. Multivariate analysis showed that high DOCK2 expression was an independent favorable prognostic factor for both EFS and OS in all patients (all P<0.05). In conclusion, our results indicated that high DOCK2 expression, in contrast to DOCK1, conferred good prognosis in AML.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2017]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2017版] 出版当年五年平均[2013-2017] 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China
通讯作者:
通讯机构: [1]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China [4]Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands [8]Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China [9]Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China [10]Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China [*1]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China. [*2]Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands [*3]Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, 518020, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)